Revenues: $39.7M; Product sales: $15.5M ; Royalty revenue: $2.8M (+55.6%); Collaborative and other R&D: $21.4M.
Net loss: ($2.6M) (+90.5%); loss/share: ($0.02) (+92.0%); Operating cash use (3 months): ($33.5M).
The increase in revenue was primarily due to the
recognition of a $20.1M upfront payment from Torii for commercialization
rights in Japan for berotralstat, and $13.9M of RAPIVAB (peramivir
injection) product sales.
Galidesivir, a broad-spectrum antiviral is currently being developed in a Phase 2 trial (Yellow Fever).
It has been shown to be active against more than
20 RNA viruses in nine different families, including coronaviruses. In
Phase 1 trials in healthy volunteers, galidesivir was generally safe and
well tolerated.
2020 guidance: Net operating cash use: $125M – 150M.
Key upcoming milestones: Berotralstat NDA accepted by FDA; PDUFA date December 3.
Berotralstat NDA for the prophylactic treatment of HAE accepted in Japan under Sakigake timeline; approval expected H2.
PNH proof of concept data with oral Factor D inhibitor, BCX9930, expected in Q2.
Report data from Phase 1 clinical trial of BCX9250 for treatment of fibrodysplasia ossificans progressiva in H2.
https://seekingalpha.com/news/3548961-biocryst-pharmaplus-8-on-q4-beat
